Analgesic nephropathy historical perspective: Difference between revisions

Jump to navigation Jump to search
No edit summary
 
(9 intermediate revisions by the same user not shown)
Line 1: Line 1:
__NOTOC__
__NOTOC__
{{Analgesic nephropathy}}
{{Analgesic nephropathy}}
{{CMG}}
{{CMG}} {{AE}} {{SHA}}
 
==Overview==
==Historical Perspective==
{{main|Phenacetin|Analgesic}}
 
[[Analgesic]]s are a class of medications widely used in the treatment of [[pain]]. They include [[aspirin]] and other [[non-steroidal anti-inflammatory drug]]s (NSAIDs), as well as the antipyretics [[paracetamol]] (known as acetaminophen in the United States) and [[phenacetin]]. Introduced in the late 19th century, phenacetin was once a common component of mixed analgesics in parts of Europe, Australia, and the United States.<ref name="pmid9734593">{{cite journal |author=McLaughlin JK, Lipworth L, Chow WH, Blot WJ |title=Analgesic use and chronic renal failure: a critical review of the epidemiologic literature |journal=Kidney Int. |volume=54 |issue=3 |pages=679–86 |year=1998 |month=September |pmid=9734593 |doi=10.1046/j.1523-1755.1998.00043.x |url=http://dx.doi.org/10.1046/j.1523-1755.1998.00043.x}}</ref> These combined analgesics contained aspirin or other NSAID with phenacetin, paracetamol, or salicylamide, and caffeine or codeine.<ref name="an-utd">{{cite book |last=de Broe |first=Marc E |editor=Curhan, Gary C (ed.) |title=UpToDate |accessdate=2008-09-30 |year=2008 |location=Waltham, MA |chapter=Analgesic nephropathy}}</ref>
 
In the 1950s, Spühler and Zollinger reported an association between kidney injury and the chronic use of phenacetin.<ref name="pmid13137299">{{cite journal |author=Spühler O, Zollinger HU |title=Die chronisch-interstitielle Nephritis. |language=German |journal=Z Klin Med |volume=151 |issue=1 |pages=1–50 |year=1953 |pmid=13137299 |doi= |url=}}</ref> They noted that chronic users of phenacetin had an increased risk of developing specific kidney injuries, namely [[renal papillary necrosis]] and [[interstitial nephritis|chronic interstitial nephritis]]. This condition was dubbed analgesic nephropathy and was attributed to phenacetin, although no absolute causative role was demonstrated. With further reports of the increased risk of kidney injury with prolonged and excessive phenacetin use, however, phenacetin was banned in several countries between the 1960s and 1980s.<ref name="pmid9734593" />
 
As the use of phenacetin declined, so too did the prevalence of analgesic nephropathy as a cause of end-stage renal disease. Data from [[Switzerland]], for example, demonstrated a decline in the prevalence of analgesic nephropathy among patients with end-stage renal disease, from 28% in 1981 to 12% in 1990.<ref name="pmid7816247">{{cite journal |author=Brunner FP, Selwood NH |title=End-stage renal failure due to analgesic nephropathy, its changing pattern and cardiovascular mortality. EDTA-ERA Registry Committee |journal=Nephrol. Dial. Transplant. |volume=9 |issue=10 |pages=1371–6 |year=1994 |pmid=7816247 |doi= |url=http://ndt.oxfordjournals.org/cgi/pmidlookup?view=long&pmid=7816247}}</ref> An autopsy study performed in Switzerland suggested that the prevalence of analgesic nephropathy in the general population has likewise decreased; the prevalence was 3% in 1980 and 0.2% in 2000.
While these data demonstrate that analgesic nephropathy has been all but eliminated in some regions, in other regions the condition persists. Notably, in Belgium, the prevalence of analgesic nephropathy among dialysis patients was 17.9% in 1984 and 15.6% in 1990.<ref name="pmid8177475">{{cite journal |author=Elseviers MM, de Broe ME |title=Analgesic nephropathy in Belgium is related to the sales of particular analgesic mixtures |journal=Nephrol. Dial. Transplant. |volume=9 |issue=1 |pages=41–6 |year=1994 |pmid=8177475 |doi= |url=http://ndt.oxfordjournals.org/cgi/pmidlookup?view=long&pmid=8177475}}</ref><ref name="pmid7753450">{{cite journal |author=Noels LM, Elseviers MM, de Broe ME |title=Impact of legislative measures on the sales of analgesics and the subsequent prevalence of analgesic nephropathy: a comparative study in France, Sweden and Belgium |journal=Nephrol. Dial. Transplant. |volume=10 |issue=2 |pages=167–74 |year=1995 |pmid=7753450 |doi= |url=http://ndt.oxfordjournals.org/cgi/pmidlookup?view=long&pmid=7753450}}</ref> Michielsen and de Schepper have suggested that analgesic nephropathy persists among Belgian dialysis patients not due to non-phenacetin analgesics, but because Belgium accepts a higher proportion of elderly patients for dialysis. According to these authors, a greater proportion have analgesic nephropathy because a greater percentage of Belgian dialysis patients have been exposed to long-term use of phenacetin.<ref name="pmid11181803">{{cite journal |author=Michielsen P, de Schepper P |title=Trends of analgesic nephropathy in two high-endemic regions with different legislation |journal=J. Am. Soc. Nephrol. |volume=12 |issue=3 |pages=550–6 |year=2001 |month=March |pmid=11181803 |doi= |url=http://jasn.asnjournals.org/cgi/pmidlookup?view=long&pmid=11181803}}</ref>
 
<br />


== Overview ==
== Overview ==
In 1953, the association between analgesic drugs and chronic renal disease was first reported in German. In 1977, Australia was first to legally ban [[phenacetin]]. In 1983, [[phenacetin]] was withdrawn from the US markets.


== Historical Perspective ==
== Historical Perspective ==


* In 1887, phenacetin was introduced as an analgesic and is metabolized to paracetamol (acetaminophen). {{cite book | last = Lemke | first = Thomas | title = Foye's principles of medicinal chemistry | publisher = Wolters Kluwer Health/Lippincott Williams & Wilkins | location = Philadelphia | year = 2013 | isbn = 9781451181135 }}
* In 1887, [[phenacetin]] was introduced as an analgesic which later became know that is metabolized to [[acetaminophen]].<ref name="Foye 2008 p.">{{cite book | last=Foye | first=William | title=Foye's principles of medicinal chemistry | publisher=Lippincott Williams & Wilkins | publication-place=Philadelphia | year=2008 | isbn=978-0-7817-6879-5 | oclc=145942325 | page=}}</ref>
* In 1893, paracetamol (acetaminophen) was introduced as an analgesic. {{cite book | last = Lemke | first = Thomas | title = Foye's principles of medicinal chemistry | publisher = Wolters Kluwer Health/Lippincott Williams & Wilkins | location = Philadelphia | year = 2013 | isbn = 9781451181135 }}
* In 1893, [[acetaminophen]] was introduced as an analgesic.<ref name="Foye 2008 p.">{{cite book | last=Foye | first=William | title=Foye's principles of medicinal chemistry | publisher=Lippincott Williams & Wilkins | publication-place=Philadelphia | year=2008 | isbn=978-0-7817-6879-5 | oclc=145942325 | page=}}</ref>
* In 1953, the association between analgesic drugs and chronic renal disease was first reported in German.<ref name="pmid13137299">{{cite journal |author=Spühler O, Zollinger HU |title=Die chronisch-interstitielle Nephritis. |language=German |journal=Z Klin Med |volume=151 |issue=1 |pages=1–50 |year=1953 |pmid=13137299 |doi= |url=}}</ref>
* In 1953, the association between [[Analgesic|analgesic drugs]] and [[Chronic renal failure|chronic renal disease]] was first reported in German.<ref name="pmid13137299">{{cite journal |author=Spühler O, Zollinger HU |title=Die chronisch-interstitielle Nephritis. |language=German |journal=Z Klin Med |volume=151 |issue=1 |pages=1–50 |year=1953 |pmid=13137299 |doi= |url=}}</ref>
* In 19.., phenacetin was withdrawn from the US markets.
* In 1977, [[phenacetin]] became legally banned in Australia.<ref name="pmid11181803">{{cite journal |author=Michielsen P, de Schepper P |title=Trends of analgesic nephropathy in two high-endemic regions with different legislation |journal=J. Am. Soc. Nephrol. |volume=12 |issue=3 |pages=550–6 |year=2001 |month=March |pmid=11181803 |doi= |url=http://jasn.asnjournals.org/cgi/pmidlookup?view=long&pmid=11181803}}</ref>  
* In 1978, [[phenacetin]] was withdrawn from the Canadian markets.<ref name="pmid6937434">{{cite journal| author=| title=Some pharmaceutical drugs. | journal=IARC Monogr Eval Carcinog Risk Chem Hum | year= 1980 | volume= 24 | issue=  | pages= 1-337 | pmid=6937434 | doi= | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=6937434  }} </ref>
*In 1980, [[phenacetin]] was withdrawn from the markets in the United Kingdom.<ref name="pmid6937434">{{cite journal| author=| title=Some pharmaceutical drugs. | journal=IARC Monogr Eval Carcinog Risk Chem Hum | year= 1980 | volume= 24 | issue=  | pages= 1-337 | pmid=6937434 | doi= | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=6937434  }} </ref>
* In 1983, [[phenacetin]] was withdrawn from the US markets.<ref name="pmid10557618">{{cite journal| author=| title=List of drug products that have been withdrawn or removed from the market for reasons of safety or effectiveness.  Food and Drug Administration, HHS. Final rule. | journal=Fed Regist | year= 1999 | volume= 64 | issue= 44 | pages= 10944-7 | pmid=10557618 | doi= | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=10557618  }} </ref>


==References==
==References==

Latest revision as of 06:12, 8 July 2020

Analgesic nephropathy Microchapters

Home

Patient Information

Overview

Historical Perspective

Pathophysiology

Differentiating Analgesic nephropathy from other Diseases

Epidemiology and Demographics

Risk Factors

Natural History, Complications and Prognosis

Diagnosis

History and Symptoms

Physical Examination

Laboratory Findings

CT

Treatment

Medical Therapy

Future or Investigational Therapies

Case Studies

Case #1

Analgesic nephropathy historical perspective On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Analgesic nephropathy historical perspective

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Analgesic nephropathy historical perspective

CDC on Analgesic nephropathy historical perspective

Analgesic nephropathy historical perspective in the news

Blogs on Analgesic nephropathy historical perspective

Directions to Hospitals Treating Analgesic nephropathy

Risk calculators and risk factors for Analgesic nephropathy historical perspective

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Associate Editor(s)-in-Chief: Shakiba Hassanzadeh, MD[2]

Overview

In 1953, the association between analgesic drugs and chronic renal disease was first reported in German. In 1977, Australia was first to legally ban phenacetin. In 1983, phenacetin was withdrawn from the US markets.

Historical Perspective

References

  1. 1.0 1.1 Foye, William (2008). Foye's principles of medicinal chemistry. Philadelphia: Lippincott Williams & Wilkins. ISBN 978-0-7817-6879-5. OCLC 145942325.
  2. Spühler O, Zollinger HU (1953). "Die chronisch-interstitielle Nephritis". Z Klin Med (in German). 151 (1): 1–50. PMID 13137299.
  3. Michielsen P, de Schepper P (2001). "Trends of analgesic nephropathy in two high-endemic regions with different legislation". J. Am. Soc. Nephrol. 12 (3): 550–6. PMID 11181803. Unknown parameter |month= ignored (help)
  4. 4.0 4.1 "Some pharmaceutical drugs". IARC Monogr Eval Carcinog Risk Chem Hum. 24: 1–337. 1980. PMID 6937434.
  5. "List of drug products that have been withdrawn or removed from the market for reasons of safety or effectiveness. Food and Drug Administration, HHS. Final rule". Fed Regist. 64 (44): 10944–7. 1999. PMID 10557618.

Template:WH Template:WS